Capricor Therapeutics Inc Forecasted to Post FY2024 Earnings of ($1.28) Per Share (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) – Equities researchers at Cantor Fitzgerald boosted their FY2024 earnings per share estimates for Capricor Therapeutics in a report released on Wednesday, September 25th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will earn ($1.28) per share for the year, up from their prior forecast of ($1.31). Cantor Fitzgerald has a “Overweight” rating and a $8.00 price objective on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.14) per share.

Several other research firms have also recently weighed in on CAPR. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday. Maxim Group upped their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Oppenheimer reissued an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $22.60.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $9.95 on Friday. Capricor Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $12.87. The firm has a fifty day moving average price of $4.80 and a two-hundred day moving average price of $5.31. The firm has a market cap of $318.19 million, a price-to-earnings ratio of -11.44 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The firm had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares in the last quarter. Marshall Wace LLP bought a new position in Capricor Therapeutics during the second quarter worth about $426,000. Renaissance Technologies LLC boosted its holdings in Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of Capricor Therapeutics in the 2nd quarter valued at approximately $147,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the period. Institutional investors own 21.68% of the company’s stock.

Insider Buying and Selling

In other news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the business’s stock in a transaction on Friday, September 20th. The stock was purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 12.00% of the stock is owned by company insiders.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.